View source for Immune checkpoint



==Immune checkpoint inhibitors==

[[Monoclonal antibody|Monoclonal antibodies]] have been developed to target immune checkpoints.
===PD-1 inhibitors===
These antibodies target the [[Programmed Cell Death 1 Receptor]] (PD-1 Receptor). Programmed Cell Death Type I is also known as [[apoptosis]]. The PD-1 Receptor is "an inhibitory T-lymphocyte receptor that has specificity for [[CD274 antigen]] and [[Programmed Cell Death 1 Ligand 2 Protein]]."<ref>{{MeSH|Programmed Cell Death 1 Receptor}}</ref>
* [[Pembrolizumab]] (Keytruda)
* [[Nivolumab]] (Opdivo)

===PD-L1 inhibitors===
* [[Atezolizumab]] (Tecentriq)
* [[Avelumab]] (Bavencio)
* [[Durvalumab]] (Imfinzi)

===CTLA-4 blockade===
The CTLA-4 Antigen is "an inhibitory [[T cell]] receptor that is closely related to [[CD28 antigen]]. It has specificity for [[CD80 antigen]] and [[CD86 antigen]] and acts as a negative regulator of peripheral T cell function. CTLA-4 antigen is believed to play role in inducing [[peripheral tolerance]]."<ref>{{MeSH|CTLA-4 Antigen}}</ref>

* [[Ipilimumab]] (Yervoy)

==See also==
* [[Cell cycle checkpoint]]

==References==
{{reflist|2}}